JNJ ▲ +0.5% - Johnson & Johnson $JNJ Johnson & Johnson: Phase 3 ICONIC-TOTAL Two-Year ICOTYDE Data Show High Complete Clearance Rates at Difficult Psoriasis Sites ? • At Week 112, 60% of patients with scalp psoriasis achieved site-specific complete skin clearance. • 89% of patients with genital psoriasis achieved site-specific complete clearance. 02-OCT-2026 06:10 AM ET